Zomedica Raises Over C$5.0 Million in First Tranche Closing

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Zomedica Raises Over C$5.0 Million in First Tranche Closing of Equity Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

ANN ARBOR, Mich., Aug. 25, 2016 (GLOBE NEWSWIRE) --   Zomedica Pharmaceuticals Corp. (TSX-V: ZOM ), a veterinary pharmaceutical company, today announced the closing of the first tranche of its recently announced non-brokered private placement offering of up to 10,000,000 common shares (each a "Common Share") at a price of C$1.50 per Common Share. 

An aggregate of 3,342,480 Common Shares have been issued for aggregate gross proceeds of approximately C$5,013,734. All of the Common Shares issued in connection with this financing are subject to a statutory four-month hold period in accordance with applicable securities laws, which will expire on December 26, 2016.

The balance of the offering (for aggregate gross proceeds of up to C$15 million) remains ongoing, with additional tranches expected to be completed upon receipt of subscription materials and subscription funds.

Zomedica expects the proceeds raised under this financing to be used for the following purposes:

  • Advancement and further development of its therapeutic pipeline;
  • Potential acquisitions, furthering its intellectual property and associated protections;
  • Capital markets activities and expenditures; and
  • General working capital purposes.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to persons in the United States absent registration or an exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Zomedica With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical company targeting health and wellness solutions for companion animals (canine, feline and equine) through a ground-breaking approach that focuses on the unmet needs of clinical veterinarians. Zomedica is building a diversified portfolio of products comprised of the discovery, development and commercialization of innovative drugs alongside novel drug delivery systems, devices and diagnostics. With multiple clinical veterinarians in executive management, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com .

Follow Zomedica

Reader Advisory Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, forward-looking information in this press release includes, but is not limited to the potential aggregate proceeds to be raised under the offering, the intended use of proceeds and the potential closing of additional tranches under the offering. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com . Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact Shameze Rampertab, CPA, CA srampertab@zomedica.com +1 647.283.3630 Media Contact Andrea Eberle aeberle@zomedica.com +1 734.369.2555

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Honda Prelude’s Hybrid Return Tests a Narrow Niche

Updated Category News Views 0

A low-slung coupe showing up in Newfoundland is not exactly a volume-sales thunderclap, and that is precisely why the 2027 Honda Prelude deserves a closer look. Steele Honda in St. John’s is presenting the hybrid two-door as a fresh choice for buyers who want something livelier than the usual practical commuter. For Honda, and for investors watching Honda Motor Co....

Continue Reading
Zoomlion’s Australian Service Push Looks Built to Last

Updated Category News Views 54

Five Australian business centres are one thing; getting a stalled crane or earthmover moving again is the whole ballgame. Zoomlion’s Nov. 4 customer gathering in Sydney matters because Chairman and CEO Zhan Chunxin kept the discussion on the unglamorous stuff: product quality, technical support, parts availability and local training. That is exactly where an equipment...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 73

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Hyster-Yale’s $135 Million Convert Carries Real Cost

Updated Category News Views 82

Forklift makers do not usually get to hide a 7.50% borrowing cost behind glossy financing jargon. Hyster-Yale has priced $135 million of convertible senior notes due in 2031, lifting the deal from the originally announced $125 million. There is also an option for initial purchasers to take another $20 million. For NYSE:HY shareholders, this is not a simple debt cleanup....

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 77

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
The Estate Bets Over $1 Billion on Luxury Longevity

Updated Category News Views 108

A billion-dollar wellness promise just wandered into the condominium market. The Estate by sbe says its first three branded residential developments carry combined real estate value above $1 billion and encompass more than 500 units. That is not pocket change, and it is certainly not a routine hotel-brand licensing exercise dressed up with scented candles and a cold...

Continue Reading
Envision’s COP31 Pitch Hinges on Grid Execution, Not Targets

Updated Category News Views 69

A 2,500 GW traffic jam is a rotten place to park climate ambition. Envision Energy used COP31 in Antalya to make the more useful point: clean-power targets mean very little if grids cannot connect, balance and dispatch the electricity. Kane Xu’s message was not another round of flag-waving promises. It was an argument that the constraint has shifted from wanting...

Continue Reading
ACOLT Bets on Gold, Craft, and a Sci-Fi Story World

Updated Category News Views 22

A gold pendant moonlighting as a plot device is not the usual luxury pitch, and thank goodness for that. ACOLT, the Denver-based men's fine jewelry house founded by Colton Hindle, plans an international December 2026 launch of its Gold Collection alongside CHRYSON Volume 1: The Arrival, an original science-fiction comic. The actual hand-forged pieces are meant to show up...

Continue Reading
Replit Bets on Trusted Creators to Sell AI Agents at Work

Updated Category News Views 201

Forty-five creators may sound like a marketing footnote, but Replit is aiming at a real enterprise bottleneck: people do not buy grand AI slogans; they buy proof that a messy internal problem can actually get fixed. Its newly launched Replit & Co. program puts business and technology creators in front of that problem, with product access, demonstrations and direct contact...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 75

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading

Top 5 Most Recently Viewed Articles

New York Times: Strong Growth Ahead with Innovative Strategies

Updated Category News Views 103

New York Times Positioned for Future Profit Growth Recently, Deutsche Bank has taken a significant step by initiating coverage on shares of the New York Times (NYSE:NYT) with a promising Buy rating and a price target of $65.00. Their analysis highlights the media company's innovative digital-first subscription model and strong fundamentals as major drivers of growth and...

Continue Reading
Maximizing Opportunities in Today's Commercial Insurance Market

Updated Category News Views 151

Understanding the Current U.S. Commercial Insurance Landscape In today’s economic climate, U.S. commercial insurance buyers are navigating one of the most advantageous periods witnessed in recent years. Despite this promising environment, the looming uncertainties affecting the economy pose challenges that require careful consideration from both buyers and insurers...

Continue Reading
Understanding the Market Activity of Dowlais Group Plc Deals

Updated Category News Views 179

Key Information About Dowlais Group Plc This disclosure pertains to an exempt principal trader engaged in client-serving transactions involving Dowlais Group Plc, providing essential insights into the movements and transactions related to its shares. Notable Dealings by the Exempt Principal Trader As highlighted, important dealings regarding the ordinary shares of Dowlais...

Continue Reading
Golden State Dermatology's Smart Expansion into Los Altos

Updated Category News Views 20

Golden State Dermatology Welcomes Todd Anhalt The Bay Area’s dermatology landscape just got an intriguing development. Todd Anhalt, a veteran dermatologist with a track record as long as a roll of duct tape, has teamed up with Golden State Dermatology (GSD). This Los Altos partnership isn't just about slapping a new name on a door—it's a strategic move to bolster...

Continue Reading
Unlocking Tesla's Future: AI, Innovation, and Growth Strategies

Updated Category News Views 117

Tesla got itself into a tight spot back in the day, trading around 40% lower than its peak. Folks were already getting antsy about where the stock was heading—had to keep an eye on those quarterly delivery numbers. The car side of things? Over 80% of projected revenues for FY24 came straight from that segment, so if it tanked, so did the whole show. Tesla's Valuation...

Continue Reading